CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 185 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 7.73 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $15,368,000 | – | 400,000 | – | 0.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $119,497,707 | 24.70% |
| Saturn V Capital Management LP | 506,818 | $11,732,837 | 8.76% |
| Octagon Capital Advisors LP | 2,551,703 | $59,071,924 | 8.50% |
| Affinity Asset Advisors, LLC | 976,021 | $22,594,886 | 7.46% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $100,599,691 | 7.28% |
| Altium Capital Management LP | 305,000 | $7,060,750 | 3.92% |
| Deep Track Capital, LP | 3,000,000 | $69,450,000 | 2.85% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 319,989 | $7,407,745 | 2.07% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,637,943 | 1.80% |
| Nicholas Investment Partners, LP | 972,191 | $22,506,222 | 1.71% |